[1]郝晨光,蔡坚.维吾尔族缺血性脑卒中患者CYP2C19*2基因多态性与氯吡格雷抵抗及卒中复发风险的相关性研究[J].第三军医大学学报,2018,40(06):523-527.
 HAO Chenguang,CAI Jian.Correlation of CYP2C19*2 polymorphism with clopidogrel resistance and risk of stroke recurrence in Uygur patients with ischemic stroke[J].J Third Mil Med Univ,2018,40(06):523-527.
点击复制

维吾尔族缺血性脑卒中患者CYP2C19*2基因多态性与氯吡格雷抵抗及卒中复发风险的相关性研究(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
40卷
期数:
2018年第06期
页码:
523-527
栏目:
临床医学
出版日期:
2018-03-30

文章信息/Info

Title:
Correlation of CYP2C19*2 polymorphism with clopidogrel resistance and risk of stroke recurrence in Uygur patients with ischemic stroke
作者:
郝晨光蔡坚
新疆医科大学第一附属医院神经内科
Author(s):
HAO Chenguang CAI Jian

Department of Neurology, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, 830054, China

关键词:
CYP2C19*2基因多态性维吾尔族缺血性脑卒中氯吡格雷抵抗
Keywords:
CYP2C19*2 gene polymorphism Uygur ischemic stroke clopidrogel resistance
分类号:
R394.5;R743.3;R966
文献标志码:
A
摘要:

目的    探讨CYP2C19*2基因多态性与维吾尔族缺血性脑卒中患者氯吡格雷抵抗及卒中复发风险的关系。方法    检测100例维吾尔族缺血性脑卒中患者CYP2C19*2基因型,分为纯合子野生型、杂合子突变型、纯合子突变型;使用血小板聚集功能检测仪测定血小板聚集率;于氯吡格雷治疗6个月时随访所有患者的卒中复发率。结果    根据基因分型,将研究对象分为纯合子野生型组(63例)、杂合子突变型组(32例)和纯合子突变型组(5例)。突变型组氯吡格雷抵抗的发生率及卒中复发率高于野生型组(P<005)。Logistic 回归分析显示:CYP2C19*2 等位基因是维吾尔族缺血性脑卒中患者氯吡格雷抵抗及卒中复发的危险因素(OR=2.541,95%CI: 1.052~6.137,P=0.038;OR=4.741,95%CI: 1.273~7.392,P=0.045)。结论    CYP2C19*2基因多态性与维吾尔族缺血性脑卒中患者氯吡格雷抵抗及卒中复发有相关性,CYP2C19*2等位基因是氯吡格雷抵抗及卒中复发的危险因素。

Abstract:

Objective    To explore the relationship of CYP2C19*2 polymorphism with clopidogrel resistance and risk of stroke recurrence in Uygur patients. Methods    The CYP2C19*2 genotype was detected in 100 patients with ischemic stroke. According to their genotypes, the patients were divided into wild type group, heterozygous mutation group and homozygous mutation group. Platelet inhibitory rates were evaluated by platelet analyzer. The incidence rate of stroke recurrence was observed in the patients after clopidogrel treatment for 6 months. Results    According to their genotypes, there were 63 patients (63%) assigned into wild type group, 32 (32%) into heterozygous mutation group and 5 (5%) into homozygous mutation group. The rates of clopidrogel resistance and stroke recurrence were significantly higher in the mutation groups than the wild type group (P<0.05). Logistic regression analysis showed the mutant allele of CYP2C19*2 was risk factor for clopidrogel resistance and stroke recurrence (OR=2.541, 95%CI: 1.052~6.137, P=0.038; OR=4.741, 95%CI: 1.273~7.392, P=0.045). Conclusion    CYP2C19*2 gene polymorphisms are associated with clopidogrel resistance and stroke recurrence in Uygur patients with ischemic stroke. The mutant alleles of CYP2C19*2 is risk factor for clopidrogel resistance and stroke recurrence.

参考文献/References:

[1]SAVER J L, CARROLL J D, SMALLING R, et al. Letter by Saver et al regarding article, “Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association”[J]. Stroke, 2015, 46(4): e85-e86. DOI: 10.1161/STROKEAHA.115.007311.
[2]WIVIOTT S D, ANTMAN E M. Clopidogrel resistance: a new chapter in a fast-moving story[J]. Circulation, 2004, 109(25): 3064-3067. DOI: 10.1161/01.CIR.0000134701.40946.30.
[3]TAN D S, YEO A H, HO H K, et al. Asian study of clopidogrel (ASCLOP) responsiveness: the contributions of genetic and non-genetic factors[J]. Int J Cardiol, 2014, 171(2): e21-e23. DOI: 10.1016/j.ijcard.2013.11.126.
[4]LIN Y J, LI J W, ZHANG M J, et al. The association between CYP2C19 genotype and of in-stent restenosis among patients with vertebral artery stent treatment[J]. CNS Neurosci Ther, 2014, 20(2): 125-130. DOI: 10.1111/cns.12173.
[5]JEONG H E, LEE S J, CHA E Y, et al. Development of a multiplex and cost-effective genotype test toward more personalized medicine for the antiplatelet drug clopidogrel[J]. Int J Mol Sci, 2014, 15(5): 7699-7710. DOI: 10.3390/ijms15057699.
[6]GUO B, TAN Q, GUO D, et al. Patients carrying CYP2C19 loss of function alleles have a reduced response to clopidogrel therapy and a greater risk of in-stent restenosis after endovascular treatment of lower extremity peripheral arterial disease[J]. J Vasc Surg, 2014, 60(4): 993-1001. DOI: 10.1016/j.jvs.2014.03.293.
[7]WANG X Q, SHEN C L, WANG B N, et al. Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome[J]. Gene, 2015, 558(2): 200- 207. DOI: 10.1016/j.gene.2014.12.051.
[8]中华医学会神经病学分会脑血管病学组急性缺血脑卒中诊治指南撰学组. 中国急性缺血性脑卒中诊治指南2010[J]. 中国医学前沿杂志(电子版), 2010, 2(4): 50-59, 69. DOI:10.3969/j.issn.1674-7372.2010.04.012.
Writing Group for Acute Ischemic Stroke Diagnosis and Treatment Guideline of Cerebrovascular Disease Group of Neurology Branch, Chinese Medical Association. Diagnosis and treatment guideline of acute ischemic stroke of China(2010) [J]. Chin J Front Med Sci(electronic version), 2010, 2(4): 50-59,69. DOI: 10.3969/j.issn.16747372.2010.04.012.
[9]FIFI J T, BROCKINGTON C, NARANG J, et al. Clopidogrel resistance is associated with thromboembolic complications in patientsundergoing neurovascular stenting[J]. Am J Neuroradiol, 2013, 34(4): 716-720. DOI: 10.3174/ajnr.A3405.
[10]PETTERSEN A A R, ARNESEN H, OPSTAD T B, et al. The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel[J]. Thromb J, 2011, 9: 4. DOI: 10.1186/1477-9560-9-4.
[11]SIBBING D, KOCH W, GEBHARD D, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement[J]. Circulation, 2010, 121(4): 512-518. DOI: 10.1161/CIRCULATIONAHA.109.885194.
[12]SCOTT S A, KATRIN S, SHULDINER A R, et al. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19[J]. Pharmacogenet Genomics, 2012, 22(2): 159-165. DOI: 10.1097/FPC.0b013e32834d4962.
[13]SCOTT S A, SANGKUHL K, STEIN C M, et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update[J]. Clin Pharmacol Ther, 2013, 94(3): 317-323. DOI: 10.1038/clpt.2013.105.
[14]ZHANG S, LAI X, LI W, et al. VASP phosphorylation and genetic polymorphism for clopidogrel resistance in Chinese patients with non-cardioembolic ischemic stroke[J]. Thromb Res, 2014, 134(6): 1272-1277. DOI: 10.1016/j.thromres.2014.10.001.
[15]JEONG T D, KIM SM, KIM H J, et al. CYP2C19 genotype and early ischemic lesion recurrence in stroke patients treated with clopidogrel[J]. J Stroke Cerebrovasc Dis, 2015, 24(2): 440-446. DOI: 10.1016/j.jstrokecerebrovasdis.2014.09.014.
[16]PAN Y, CHEN W, XU Y, et al. Genetic polymorphisms and clopidogrel efficacy for acute ischemic stroke or transient ischemic attack: a systematic review and metaanalysis[J]. Circulation, 2017, 135(1): 21-33. DOI: 10.1161/CIRCULATIONAHA.116.024913.
[17]WANG Y, ZHAO X, LIN J, et al. Association between CYP2C19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack[J]. JAMA, 2016, 316(1): 70-78. DOI: 10.1001/jama.2016.8662.
[18]HOH B L, GONG Y, MCDONOUGH C W, et al. CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease[J]. J Neurosurg, 2016, 124(6): 1746-1751. DOI: 10.3171/2015.6.JNS15795.
[19]周晓辉, 张小宁, 郝晨光, 等. 新疆地区维吾尔族和汉族50岁以上人群脑卒中及血管性痴呆流行病学调查[J]. 中华流行病学杂志, 2008, 29(10): 1049-1050. DOI: 10.3321/j.issn:02546450.2008.10.023.
ZHOU X H, ZHANG X N, HAO C G, et al. Epidemic investigation of prevalence of stroke and vascular dementia among uygur and Han nationalities(≥50 years)in Xinjiang[J]. Chin J Epidemiol, 2008, 29(10): 1049-1050. DOI: 10.3321/j.issn:0254-6450.2008.10.023.

相似文献/References:

[1]张政,罗勇军,晏宁,等.GABBR1基因G1465A多态与中国汉族青少年肌阵挛癫痫的关系[J].第三军医大学学报,2007,29(15):1488.
 ZHANG Zheng,LUO Yong-jun,YAN Ning,et al.G1465A polymorphism of GABBR1 gene is associated with juvenile myoclonic epilepsy in Chinese Han nationality[J].J Third Mil Med Univ,2007,29(06):1488.
[2]李代蓉,周清华,郭占林,等.CYP2E1基因多态性与肺癌遗传易感性的关系[J].第三军医大学学报,2008,30(13):1231.
 LI Dai-rong,ZHOU Qing-hua,GUO Zhan-lin,et al.Association between genetic polymorphisms of CYP2E1 and lung cancer susceptibility: a case control study[J].J Third Mil Med Univ,2008,30(06):1231.
[3]罗勇军,高文祥,高钰琪,等.26例健康汉族人线粒体DNA region V 9 bp缺失多态性的检测[J].第三军医大学学报,2007,29(03):191.
 LUO Yong-jun,GAO Wen-xiang,GAO Yu-qi,et al.Polymorphism of deletion in mitochondrial DNA region V among 26 Han Chinese[J].J Third Mil Med Univ,2007,29(06):191.
[4]田波,李启富,龚莉琳,等.重庆地区汉族人群TRB3基因+251A/G多态性与多囊卵巢综合征的相关性分析[J].第三军医大学学报,2011,33(15):1559.
 Tian Bo,Li Qifu,Gong Lilin,et al.Correlation of TRB3 gene +251A/G polymorphism with polycystic ovarian syndrome: a report of 139 cases in Chongqing Han population[J].J Third Mil Med Univ,2011,33(06):1559.
[5]孙艳荪,苏本利,李昌臣.解偶联蛋白2基因多态性与糖尿病视网膜病变关系的研究[J].第三军医大学学报,2006,28(15):1614.
[6]刘元丰,江军,王洛夫,等.雄激素受体基因多态性与前列腺癌关系的研究[J].第三军医大学学报,2005,27(10):1036.
[7]王亚林,江军,王洛夫,等.GSTM1、GSTT1基因多态性与中国人前列腺癌风险关系[J].第三军医大学学报,2005,27(10):1039.
[8]邓少丽,李艳林,陈鸣,等.MIF水平及MIF-173 G/C多态性与结核病关系研究[J].第三军医大学学报,2010,32(24):2616.
 Deng Shaoli,Li Yanlin,Chen Ming,et al.Relationship of serum MIF level and -173G/C polymorphism with tuberculosis: a retrospective study on 68 cases[J].J Third Mil Med Univ,2010,32(06):2616.
[9]万顺梅,房殿春,杨仕明,等.人端粒酶催化亚单位基因单核苷酸多态性与胃癌的关系[J].第三军医大学学报,2008,30(07):603.
 WAN Shun-mei,FANG Dian-chun,YANG Shi-ming,et al.Association of single nucleotide polymorphism of hTERT candidate genes with gastric carcinoma[J].J Third Mil Med Univ,2008,30(06):603.
[10]马剑华,文建强,马恩和,等.甘肃裕固族、东乡族、保安族人群CD14基因启动子区-159C/T多态性研究[J].第三军医大学学报,2012,34(01):87.

更新日期/Last Update: 2018-03-23